Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
PDS Biotechnology Corporation - Common Stock
(NQ:
PDSB
)
0.2885
-0.0115 (-3.83%)
Streaming Delayed Price
Updated: 1:45 PM EDT, Sep 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about PDS Biotechnology Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
The trading volume of these stocks is deviating from the norm in today's session.
↗
Today 13:00 EDT
Via
Chartmill
Top movers analysis one hour before the close of the markets on 2026-09-08: top gainers and losers in today's session.
↗
September 08, 2026
Via
Chartmill
Curious about the most active stocks on Tuesday?
↗
September 08, 2026
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
September 08, 2026
Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million. PDS Biotechnology...
Via
Benzinga
Top movers analysis in the middle of the day on 2026-09-08: top gainers and losers in today's session.
↗
September 08, 2026
Via
Chartmill
PDS Biotech (NASDAQ:PDSB) Posts Narrower Q1 Loss, Pre-Market Rises Over 5%
↗
May 13, 2026
Via
Chartmill
Earnings Scheduled For November 13, 2025
↗
November 13, 2025
Via
Benzinga
Insights into PDS Biotechnology's Upcoming Earnings
↗
August 12, 2025
Via
Benzinga
There are notable gap-ups and gap-downs in today's session.
↗
September 08, 2026
Via
Chartmill
These stocks have an unusual volume in today's session
↗
August 13, 2026
Via
Chartmill
What's going on in today's session
↗
August 11, 2026
Via
Chartmill
Here are the top movers in Tuesday's session.
↗
August 11, 2026
Via
Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session.
↗
August 11, 2026
Via
Chartmill
Insights Ahead: PDS Biotechnology's Quarterly Earnings
↗
May 13, 2025
Via
Benzinga
PDSB Q4 2025 Earnings Call Transcript
↗
May 27, 2026
PDSB Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Intellectual Property
PDSB Q1 2026 Earnings Transcript
↗
May 13, 2026
PDSB Q1 2026 Earnings Transcript
Via
The Motley Fool
Topics
Intellectual Property
PDS Biotechnology Q1 Earnings Call Highlights
↗
May 13, 2026
PDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and...
Via
MarketBeat
Topics
Earnings
What's going on in today's after hours session
↗
March 20, 2026
Via
Chartmill
PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) Reports Q3 2025 Earnings Beat, Stock Surges 64% in Pre-Market
↗
November 13, 2025
PDS Biotech (PDSB) Q3 2025 earnings beat EPS estimates, sparking a major pre-market surge. The clinical-stage biotech also announced key progress for its lead cancer therapy.
Via
Chartmill
Topics
Earnings
A Look Ahead: PDS Biotechnology's Earnings Forecast
↗
November 12, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
November 11, 2025
Via
Benzinga
PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval
↗
October 30, 2025
The company requested a meeting with the FDA to discuss an accelerated approval pathway for its lead cancer drug, PDS0101, following strong final data from its VERSATILE-002 trial.
Via
Stocktwits
Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026
↗
October 30, 2025
Q3 revenue of $995.7 million beat Align’s own forecast range of $965 million to $985 million, fueled by strong growth in clear aligners for teens and kids.
Via
Stocktwits
PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) Reports Narrower Q2 2025 Loss, Stock Rises on Clinical Progress
↗
August 13, 2025
PDS Biotechnology (PDSB) reported Q2 2025 EPS of -$0.21, beating estimates. Stock rose 8.13% pre-market as clinical progress, including ASCO presentations, boosts investor optimism. No revenue yet.
Via
Chartmill
PDSB Loss Improves as Costs Drop
↗
August 13, 2025
Via
The Motley Fool
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
July 16, 2025
Via
Benzinga
Earnings Scheduled For August 13, 2025
↗
August 13, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
May 23, 2025
Via
Benzinga
PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish
↗
March 27, 2025
The company said the reduced losses were primarily due to decreased operating expenses.
Via
Stocktwits
Earnings Scheduled For May 14, 2025
↗
May 14, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.